# Evidence D: Clinical review, prescribing, pharmacy fulfillment

**Status:** first pass complete, 2026-10-19 (PT). Live probes 2026-10-19 PT / 2026-10-20 UTC.
**Scope:** from a booked GLP-1 visit → clinician review → tirzepatide decision → eRx → pharmacy order → fill/delivery → week-4 titration. Acquisition, signup, intake questionnaire detail, lab ordering detail, and card capture are other evidence files; this file covers only what changes at the clinical/pharmacy handoff.
**Reader:** technology plan + operating plan. Every claim is tagged. Unknowns are explicit.

---

## 0. Method, system map, and Corrections

### 0.1 Sources actually used

- Recovered consumer source: `src/sources/first-party/` (routes, RTK evidence files, components, hardcoded category copy).
- Internal portal recon: `osint/internal_portals_recon.json` (Visitron 98 paths / 91 RTK ops / 33 tags; Catalog 47/106; Referrals 18/27; Provider Chat 20/14).
- Live public GETs against `generalmedicine.co` and its own `/api/external/*` proxy (no auth, no forms, no checkout). Prices and pharmacy rows below are live API payloads, not dossier prose.
- Public primary sources: Zepbound SPL/label, Mounjaro SPL/label, LillyDirect FAQ, Zepbound savings-card terms, NPPES, Walmart release, Pharmacy Times.
- Dossiers: `architecture.md`, `api-spec.md`, `data-models.md`, `openapi.yaml`, `adversarial-and-market-report.md`, `generalmedicine.md`, and the briefing appendix.

### 0.2 System map on this path

| Layer | System | Role | Evidence |
|---|---|---|---|
| Storefront | Next.js 14 App Router (`generalmedicine.co`) | GLP-1 eval PDP, visit options, compare-pharmacies drawer, pharmacy directory, pharmacy order UI | `[CODE app/…; components/VisitOptions/*; components/ProductDetailPage/*]` |
| Core API | Nile-Core, Ruby on Rails (`api.generalmedicine.co`) | Visits, prescriptions, pharmacy orders, pricing, care journeys, messaging | `[DOC architecture.md §1, §9]` |
| Clinician UI | **Visitron** (`visitron.internal.generalmedicine.co`, `visitron.staging-nile.com`) | Appointment → chart → encounter → care pathway → eRx → benefit check → next-step review → shift checkout | `[DATA osint/internal_portals_recon.json → visitron]` |
| EHR of record | **Athenahealth** | Encounter/care-plan write-back, chart resync, patient `athena_id` | `[CODE Visitron ops sync_encounter_to_athena, care_plan_athena_resync, encounter_summary_athena_resync]`; role per `[DOC architecture.md §8.2]` |
| eRx | **DoseSpot** | SSO, draft/finalize Rx, patient meds, inbound refill requests, RTPB/formulary | `[CODE Visitron ops dose_spot_sso, createDraftPrescription, finalizeDraftPrescription, prescription_eligibility_inquiries/*]` |
| Ambient scribe | **Nabla** | Scribe status only; note drafting | `[CODE Visitron op get_nabla_status]`; role `[DOC architecture.md §8.2]` |
| Benefit check | **Arrive Health** | RTPB launch + patient context; returns copay/formulary/PA signal and `arrive_rtpbi_inquiry_id` | `[CODE /api/internal_oauth/arrive_health/launch_benefit_inquiry, patient_context]`; `[CODE lib/store/api/pharmacyOrderApi.ts:99]` |
| HIE | **Metriport + Particle Health** | Longitudinal records, meds, allergies; prewarm | `[CODE Visitron op trigger_metriport_sync]`; `[DOC generalmedicine.md §7]` |
| Payments | **Stripe** | SetupIntent / payment method / checkout | `[CODE lib/api/endpoints.ts:321-328]`; `[LIVE https://generalmedicine.co/terms-of-service, 2026-10-19]` |
| Pharmacy IDs | **NCPDP** provider IDs | Routing key sent on `select_pharmacy` | `[CODE lib/store/api/pharmacyOrderApi.ts:90-103]` |
| Manufacturer pharmacy | **LillyDirect Pharmacy, LLC** (NCPDP `1574056`, NPI `1912889320`) | NCPDP endpoint for Zepbound/Foundayo; actual dispensing by third parties | `[LIVE /api/external/pharmacy_detail_pages/88334, 2026-10-19]`; `[PUBLIC NPPES 1912889320]` |
| Manufacturer pharmacy | **NovoCare** (NCPDP `5758074`, NPI `1710671854` = CoAssist Pharmacy, LLC) | NCPDP endpoint for Wegovy | `[LIVE /api/external/pharmacy_detail_pages/84293, 2026-10-19]` |
| Mail pharmacy | **Amazon Pharmacy** (NCPDP `5919177`, NPI `1285084467` = A.E. Pharmacy, LLC) | Mail-order eRx endpoint | `[LIVE /api/external/pharmacy_detail_pages/36035, 2026-10-19]` |
| Retail | CVS / Walgreens / Walmart / other | Pickup, insurance adjudication, GM card | `[CODE components/ProductDetailPage/PharmacyQuickFilters.tsx:11]` |
| Payer/PBM | Patient's plan | Claim adjudication, PA, copay | `[INFERENCE]` from insurance billing type and PA copy |
| Professional entity | Emerald PCs (AZ, CA, KS, ID, NJ per current legal docs) | Furnishing/billing entity for Emerald telehealth | `[LIVE /terms-of-service, /telehealth-informed-consent]` |
| Delegated network | OpenLoop / Reliant.MD / MECNB under “Vital” consent | Alternative furnishing network, state variants | `[LIVE /vital-informed-consent, 2026-10-19]` |

### 0.3 Corrections to the brief and prior dossiers

These are the places where the evidence changes the working assumption. Read these before the tables.

1. **Chat is cash-only.** The GLP-1 evaluation sells **chat at $30 cash** with **no insurance sub-option**. Video is **$100 cash or $25 estimated insurance**. So “insured $25” applies to video (and e-consult), not chat. `[LIVE https://generalmedicine.co/s/glp-1-medication-evaluation/300543, 2026-10-19]`; `[LIVE /api/external/sku_options/300543, 2026-10-19]`
2. **ACR is not the GLP-1 pathway.** GLP-1 evaluation (`300543`) exposes only `video` and `chat`; its price options carry no `allows_acr` and no in-person option. ACR is a per-option async-review capability (`allows_acr`) that the code comment associates with in-person SKUs; where enabled, `checkout_fee` bundles `coordination_fee` + `clinical_review_fee` (live example `300603`: 3000 + 1500 = 4500). The ACR escalation SKU `300591` is a real follow-up video visit, but it is not the default GLP-1 path. `[CODE components/VisitOptions/OfficeVisitOption.tsx:52-57]`; `[CODE types/enums/sku-constants.ts:7-8]`; `[LIVE /api/external/sku_options/300603, 2026-10-19]`
3. **Compounded GLP-1 is not offered.** No compounded semaglutide/tirzepatide SKU exists in the 3,184-URL sitemap, the live search index, or the recovered source. Searching `compounded` returns lexical matches (Diclofenac, CombiPatch), not a compounded GLP-1. `[DATA osint/live_sitemap_skus.json → sitemap_only_skus]`; `[LIVE /api/external/search/index?query=compounded, 2026-10-19]`; `[CODE grep: no “compounded” in ts/tsx]`
4. **The default Zepbound PDP is the most expensive form.** `/s/zepbound-tirzepatide/201448` canonicalizes to `/dp/zepbound/710642`, whose `selected_sku_id` is the **auto-injector at $1,074.09**. The **KwikPen** is a separate option: 2.5 mg `$299`, 5 mg `$399`, 7.5–15 mg `$449`. The “from $299” on the Lilly partner page is the KwikPen/self-pay tier, not the default PDP price. `[LIVE /api/external/product_detail_pages/710642, 2026-10-19]`; `[LIVE /api/external/medication_option_skus/710642/cash_price = 107409]`; `[LIVE https://generalmedicine.co/p/lilly/weight-loss, 2026-10-19]`
5. **Vials are unpriced and not routed to LillyDirect.** “Injectable solution” (single-dose vial) SKUs return `total_price_cents: null` and their pharmacy comparison contains only retail rows (no LillyDirect), even though vials are the canonical LillyDirect self-pay format. The cheapest self-pay format is effectively not purchasable through GM’s storefront. `[LIVE /api/external/medication_option_skus/701542/cash_price = null]`; `[LIVE /api/external/pharmacy_comparisons?medication_option_sku_id=701542, 2026-10-19]`; `[LIVE /api/external/pharmacy_detail_pages/88334/medications, 2026-10-19]` (only `710641` and `706450`)
6. **LillyDirect is not one fulfillment partner.** `LillyDirect Pharmacy, LLC` is the NCPDP endpoint (`1574056`), but LillyDirect’s own FAQ names **Amazon Pharmacy, Fuze Health, Gifthealth, Prescryptive, and Walmart Pharmacy** as third-party dispensing pharmacies; the dispensing pharmacy depends on medicine, delivery method, and payment method. `[LIVE https://www.lilly.com/lillydirect/faq, 2026-10-19]`; `[PUBLIC NPPES 1912889320 = LILLYDIRECT PHARMACY, LLC, former legal name BALANCE PHARMACY SERVICES LLC]`
7. **The Friendly-PC list in the legal docs does not match NPPES.** Current Terms (rev. 2026-09-16) and Telehealth Consent name **Emerald Medical Practice, P.C. (AZ), Emerald Medical Practice, P.A. (KS), Emerald Medical Practice, P.C. (CA), Ruby Medical Practice, P.C. (NJ), Centennial Medical Practice, P.C. (ID)**. The NPPES records behind the three known PC names resolve to **Emerald (UT, two NPIs), Centennial (FL), Ruby (NJ)**; I did not find separate AZ/KS/CA/ID enumerations for those names. NPPES may not reflect every state registration, so treat the state→PC matrix as unresolved. `[LIVE /terms-of-service; /telehealth-informed-consent]`; `[PUBLIC NPPES 1447011267, 1750195483, 1174333975, 1346050150]`
8. **`in_stock` is not real.** `data-models.md` includes `PharmacyComparisonResult.in_stock`, but the live `pharmacy_comparisons` payload has no `in_stock`, no hours, no city/state, and no tracking. Only `chain_name`, `fulfillment_owner`, `ncpdp_provider_id`, `friendly_id`, `address_line1`, `distance_miles`, `latitude`, `longitude`, `total_price_cents`. There is no inventory signal to automate out-of-stock handling. `[LIVE /api/external/pharmacy_comparisons?medication_option_sku_id=710641&latitude=37.7749&longitude=-122.4194, 2026-10-19]`
9. **Billing-type enum is inconsistent client vs server.** Client code checks `'gm_card'` and `'pharmacy_delegated'`; the OpenAPI/API spec enum is `'cash' | 'insurance' | 'pharmacy_delegation'`. Either the server accepts aliases or one branch is dead. `[CODE lib/utilities.ts:949-955]`; `[DOC openapi.yaml:257-262, 1241-1246]`
10. **“We take care of prior authorizations” is marketing, not a recovered workflow.** There is no PA object, queue, or submit operation in the consumer API or Visitron’s 91 ops. Arrive Health and DoseSpot expose RTPB only; no CoverMyMeds/Surescripts/PA vendor is present in source or DNS. The Assignment of Benefits says pre-authorization is the **patient/referring physician’s** responsibility. `[CODE lib/hardcoded-data/CategoryPages/medications.ts:43]`; `[LIVE /assignment-of-benefits, 2026-10-19]`; `[DATA osint/internal_portals_recon.json → visitron]`
11. **The Lilly partner page’s Zepbound CTA points at a SKU that does not allow first fill.** `201448` has `allows_first_fill: false`, `allows_refill: true`, yet the Lilly page’s Zepbound card links to `/s/sku/201448/screen`. The new-start path is the GLP-1 evaluation `300543`. This is a funnel/eligibility mismatch worth fixing or explaining. `[DATA osint/extracted_care_plans_and_journeys.json → 201448.modalities]`; `[LIVE https://generalmedicine.co/p/lilly/weight-loss, 2026-10-19]`
12. **Catalog quantity/unit is internally inconsistent.** For a 28-day weekly injection: Zepbound auto-injector `default_quantity: 2.0` “Auto-injectors”; Zepbound KwikPen `2.4` “Injection pens”; Mounjaro `1.0` “Auto-injector”. These look like mL totals with a mislabeled unit, and Mounjaro’s 1.0 mL is half of a 4-pen 28-day supply. Do not generate Rx quantity from these fields without verification. `[LIVE /api/external/product_detail_pages/710642, 710655, 201448, 2026-10-19]`

---

## 1. Steps and label-based clinical regimen

Day/time is relative to the organic Google click (D0). this file starts once the patient has chosen a visit; upstream acquisition/intake is out of scope. “T” = scheduled visit start.

**Routing summary (direct answer).** A GLP-1 case reaches a clinician in one of two ways: (1) a scheduled **video** visit (`video_visit`; Zoom; $100 cash / $25 est. insurance), or (2) a **chat** visit (`chat_visit`; $30 cash; next available window, live availability promise was next-day 10:00 MT). Both are created at booking and surfaced in Visitron’s appointment/chat queues. GLP-1 does **not** enter the ACR queue: `300543` has no `allows_acr` option. If a case were ACR-enabled, Visitron would use `getAsyncClinicalReview` / `submitAsyncClinicalReview`, with `300591` as the video escalation. `[LIVE /api/external/sku_options/300543]`; `[DATA internal_portals_recon.json → visitron]`; `[CODE types/enums/sku-constants.ts:7-8]`

| Step | Day/time | Patient sees / does | GM system, screen, route | Data captured / emitted | Evidence |
|---|---|---|---|---|---|
| **D1** | D0 + 10–30 min | Opens GLP-1 evaluation page. Sees **Video $25 est. / $100 w/o insurance** and **Chat $30 w/o insurance**. Picks modality; picks a slot (video) or accepts next available chat window. | `/s/glp-1-medication-evaluation/300543` → `/options` → `POST /api/external/visits/:id/booking_selection` → `POST /visits/:id/payment_method` → `POST /visits/book`. Visit cart keyed on `localStorage['general-ai-visit-id']`. | `sku_id=300543`; modality `video`/`chat`; slot or availability promise; payment method; price shown; state; attribution `ref`. | `[LIVE https://generalmedicine.co/s/glp-1-medication-evaluation/300543, 2026-10-19]`; `[LIVE /api/external/sku_options/300543, 2026-10-19]`; `[CODE lib/api/endpoints.ts:82-92]`; `[CODE lib/store/api/visitCartApi.ts:58-123]` |
| **D2** | D0 + 20–30 min | Confirms physical location/state before screening. May be asked for ID and to confirm location again at visit. | `/s/{sku-name}/{sku-id}/location-confirmation`; `appointment_location_state` appended to `GET /api/external/sku_options/:skuId`; server is expected to filter the clinician pool (not directly observed). `practiceId` carried through booking from the insurance flow. | `state`; `practice_id`; clinician pool; booking eligibility. | `[CODE lib/routes/skuBooking.ts:53-59]`; `[CODE lib/api/endpoints.ts:132-136]`; `[CODE lib/redirectFromInsuranceFlow.ts:11-12, 147-181]`; `[DOC architecture.md §10.6]`; `[LIVE /telehealth-informed-consent]` |
| **D3** | D0 (video, promise “today”) or D0+1 ~10:00 MT (chat promise) | Waits; receives SMS/email visit link. For chat, waits for clinician to join the text thread. | Visitron `ProviderAppointments` / `PatientAppointments`; `getAppointmentInfo`; `requestChatVisit`; `getProviderNotifications`; `open_visit`. Patient side uses visit room / Zoom link / chat thread (Twilio Conversations per dossier). | `appointment_id`; `visit_type`; `patient_id`; `clinician_id`; `state`; `meeting_url` (video). | `[DATA osint/internal_portals_recon.json → visitron.rtk_endpoints]`; `[LIVE /api/external/sku_options/300543]` (`availability_promise` `2026-10-20T10:00:00-06:00` for chat, `today` for video); `[LIVE https://generalmedicine.co/using-zoom, 2026-10-19]` |
| **D4** | T − 10 min | Nothing. | Clinician opens chart: `applyAppointmentLatestPrewarm`, `getPatientChartContext`, `getPastVisits`, `triggerMetriportSync`, `getQuestionnaireCodes`, `getSkus`. | HIE history (Metriport/Particle), prior GM encounters, meds, allergies, questionnaire responses, SKU context. | `[DATA osint/internal_portals_recon.json → visitron]`; `[DOC generalmedicine.md §7]`; `[DOC architecture.md §8.2]` |
| **D5** | T to T+15–45 min | Video: joins Zoom, camera required. Chat: exchanges messages in the visit thread; can text 98528 if disconnected. | Visitron `getDraftEncounter`, `updateDraftEncounter`, `getChatHistory`, `getNablaStatus`, `getAdHocEncounterInfo`; video transport is Zoom; chat transport is the visit/message thread. | Transcript/audio; note draft; encounter time; diagnoses discussed; orders; chat messages. | `[LIVE /using-zoom]` (Zoom app, unique link, 98528); `[DATA internal_portals_recon.json → visitron]`; `[DOC architecture.md §10.2]` |
| **D6** | During D5 | Describes weight history, prior attempts, comorbidities, current meds, side effects, goals. Clinician screens BMI and contraindications; may order baseline labs. | Clinical decision uses GM’s GLP-1 guide + product labels. Visitron `searchDiagnoses`, `getIcd10Codes`, `getLabCodes`, `getQuestionnaireCodes`; orders via `Orders` / `getEncounterOrders`. | Height, weight, BMI (Zepbound weight-management criteria: BMI ≥30, or ≥27 with a weight-related comorbidity; Mounjaro is T2D and has **no BMI threshold**); comorbidities (HTN, dyslipidemia, T2D, OSA, CVD); label §4 contraindications (MTC/MEN2, serious hypersensitivity); protocol precautions (pancreatitis, gastroparesis, eating disorder, pregnancy); prior GLP-1; baseline labs (HbA1c, CMP, TSH, lipids). | `[LIVE https://generalmedicine.co/resources/using-a-glp-1-for-weight-loss, 2026-10-19]`; `[PUBLIC Zepbound SPL §1, §2.2, §4]`; `[PUBLIC Mounjaro SPL §1, §2.1]`; `[DATA internal_portals_recon.json → visitron]` |
| **D7** | During/after D5 | Nothing directly; later sees care-plan phases/check-ins. | Visitron `getPublishedPathways`, `createCareJourney`, `changePathway`, `changePhase`, `batchChangePatientMedicationPhases`, `updatePatientMedicationDaysSupply`, `updatePatientMedicationCourseType`. Catalog authors `care_pathways`, `sku_phases`, `phase_modality`, `criteria_sets`, `requirements`. | `pathway_id`; `phase_id`; modality; check-in cadence; days supply; course type. | `[DATA internal_portals_recon.json → visitron, catalog]`; `[DOC generalmedicine-executive-briefing.html App. F.06]` (5-phase synthesis) |
| **D8** | T+30–60 min | Nothing; later sees prescription in care plan. | Visitron `createDraftPrescription` → `updateDraftPrescription` → `finalizeDraftPrescription`; `replaceDraftPrescription`; `cancelDraftPrescription`; `createPatientMedicationPrescriptionRenewal`; DoseSpot SSO (`dose_spot_sso`) and `getDoseSpotIdpStatus`. | Drug (tirzepatide), strength (2.5/5/7.5/10/12.5/15 mg), form (KwikPen/auto-injector/vial), quantity, days supply (28), refills, SIG, diagnosis, later pharmacy NCPDP ID. | `[DATA internal_portals_recon.json → visitron]`; `[CODE /api/internal_oauth/visitron/dose_spot_sso]`; `[PUBLIC Zepbound SPL §2.2]` |
| **D9** | T+30 min → D+5 business days | Sees “available after visit” / “est. insurance price”; later may see copay or PA request. | Visitron `launchInsurancePrice`, `getInsurancePriceStatus`, `launch_benefit_inquiry`, `getDoseSpotIdpStatus`, DoseSpot `prescription_eligibility_inquiries/{launch,formulary,sync_insurance}`. Consumer polls `/api/external/pharmacy_pricing/insurance/:inquiryId`. | Copay tier; deductible; formulary status; PA required; `arrive_rtpbi_inquiry_id`; plan/payer name. | `[CODE components/ProductDetailPage/MedicationPriceCard.tsx:14-15]`; `[CODE lib/api/endpoints.ts:345-348]`; `[DATA internal_portals_recon.json → visitron]`; `[LIVE /dp/zepbound/710642]` (“Available after visit”); `[LIVE GLP-1 guide]` (“several business days”) |
| **D10** | T+45–60 min | Later sees signed care plan/next steps. | Visitron `confirmCarePlan`, `publishAppointmentDraftEncounter`, `syncEncounterToAthena`, `generateNextStepReview`, `createNextStepReview`, `updateNextStepReview`; resync ops. | Signed encounter note; care plan; orders; `athena_id`; next-step review. | `[DATA internal_portals_recon.json → visitron]`; `[DOC architecture.md §8.2]` |
| **D11** | D+1–24 h (patient action) | Opens prescription in care plan/dashboard; taps to order. | `POST /api/external/prescriptions/:careActionPrescriptionId/ensure_pharmacy_order` → `{ pharmacy_order_id }`; order state `created` per the client data model. | `care_action_prescription_id`; `pharmacy_order_id`; `medication_sku_id`; `state=created`. | `[CODE lib/store/api/prescriptionApi.ts:24-32]`; `[CODE lib/api/endpoints.ts:235-240]`; `[DOC architecture.md §9.1 step 1]`; `[DOC data-models.md §2.4]` |
| **D12** | D+1–24 h | Opens “Compare pharmacies”; sees the featured manufacturer pharmacy (LillyDirect or NovoCare, when present) and Amazon pinned ahead of the nearby/online interleave; nearby retail is interleaved 2:1. Selects a pharmacy. | `GET /api/external/pharmacy_comparisons?medication_option_sku_id=&latitude=&longitude=`; `POST /api/external/pharmacy_orders/:id/select_pharmacy` with `ncpdpProviderId` + optional `arrive_rtpbi_inquiry_id`. | NCPDP ID; `total_price_cents`; `fulfillment_owner`; distance; `friendly_id`; inquiry ID. | `[CODE lib/store/api/pharmacyComparisonApi.ts:13-21]`; `[CODE lib/api/endpoints.ts:120-124]`; `[CODE lib/store/api/pharmacyOrderApi.ts:90-103]`; `[CODE components/Refresh/SearchResults/searchPharmaciesUtils.ts:22-28, 140-155]` |
| **D13** | D+1–24 h | Chooses **cash / GM card**, **insurance**, or **pay at pharmacy**. | `PATCH /api/external/pharmacy_orders/:id` `{ billing_type }`. Client checks `gm_card`, `insurance`, `pharmacy_delegated`; server enum is `cash`, `insurance`, `pharmacy_delegation`. | `billing_type`; payment method; insurance estimate; `hasClinicalReview` flag (source of flag not recovered). | `[CODE lib/utilities.ts:949-955]`; `[CODE lib/store/api/pharmacyOrderApi.ts:34-44]`; `[DOC openapi.yaml:1232-1246]`; `[DOC architecture.md §9.1 step 4]` |
| **D14** | D+1–24 h | Cash: pays GM by card; gets a prepaid card by text. Insurance: no app charge; pays copay at counter. Pay-at-pharmacy: shows GM card at counter. | `POST /pharmacy_orders/:id/checkout` (Stripe) or `/checkout_with_insurance` or `/checkout_for_pharmacy_delegation`; `GET /pharmacy_orders/:id/gm_card`; `GET /invoice`. | `payment_method_id`; `return_url`; `payment_intent`; `gm_card { bin, pcn, group, member_id }`. | `[CODE lib/store/api/pharmacyOrderApi.ts:61-118]`; `[DOC openapi.yaml:1338-1420]`; `[LIVE https://generalmedicine.co/resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup, 2026-10-05]` |
| **D15** | At/after checkout | Nothing; pharmacy receives Rx. | DoseSpot eRx → selected NCPDP ID; `select_pharmacy` is the routing trigger. Transmission protocol is not visible in the client. | Rx payload; NCPDP ID; patient demographics; prepaid/discount status. | `[CODE lib/store/api/pharmacyOrderApi.ts:90-103]`; `[DATA internal_portals_recon.json → visitron escribe]`; `[INFERENCE]` NCPDP SCRIPT via DoseSpot, based on DoseSpot eRx + NCPDP IDs |
| **D16** | Same day–5 business days | Retail: gets pickup notification. LillyDirect: gets text/email from dispensing pharmacy, then a checkout link; pays the pharmacy. | Retail pharmacy system adjudicates/dispenses. LillyDirect dispensing pharmacy verifies, checks insurance/PA, applies savings, sends checkout link, ships. | Rx status; copay; PA status; checkout link; savings applied; shipment. | `[LIVE https://www.lilly.com/lillydirect/faq, 2026-10-19]` (3–5 business days verification; dispensing pharmacy contacts patient); `[LIVE /pharmacy/walgreens-pharmacy/73542]` |
| **D17** | 1–4 days after checkout (LillyDirect); same day (retail) | Receives package or picks up. Most LillyDirect shipments do not require a signature; refrigerated packages may have specific delivery requirements. | No GM shipping object. Cold chain handled by dispensing pharmacy. | Tracking (pharmacy-side); delivery confirmation; no GM fields observed. | `[LIVE LillyDirect FAQ]` (free delivery; 1–4 days; cold-chain; most shipments no signature); `[PUBLIC Zepbound SPL §16.2]`; `[PUBLIC Mounjaro SPL §16.2]` |
| **D18** | Day 28 of dosing | Gets a check-in card/notification. Completes questionnaire and/or labs; may book a follow-up. | `GET /api/external/care_journey/next_steps` → 3 groups (`Questionnaire`, `Lab`, `Visit`) with `locked`, `available_at`, `soonest_deadline`, `estimated_minutes`; `/prescriptions/:id/check-in`; `POST /care_journey/lab_bundle`; `POST /patient_medications/:id/lab_bundle`; `POST /visits/...`. | Criteria IDs; questionnaire responses; lab order ID; visit ID; deadline. | `[CODE lib/store/api/careJourneyApi.ts:39-83]`; `[CODE lib/careJourney.ts:1-2]`; `[CODE lib/prescriptions/prescriptionCheckInFlow.ts:1-100]`; `[LIVE GLP-1 guide]` (“monthly while titrating”) |
| **D19** | Day 28 | Follow-up visit: **Chat $30 cash** or **Video $25 est. / $100 cash**. Clinician reviews tolerance and adjusts dose per label (usually 2.5 → 5 mg after 4 weeks). | Visitron `getClinicianReviews`, `applyReview`, `rejectReview`, `confirmNoChange`, `changePhase`, `createPatientMedicationPrescriptionRenewal`, `createDraftPrescription`, `finalizeDraftPrescription`. | New dose (e.g., 2.5 → 5 mg), new Rx, phase change, days supply, refills. | `[DATA internal_portals_recon.json → visitron]`; `[PUBLIC Zepbound SPL §2.2]`; `[LIVE https://generalmedicine.co/s/weight-loss-follow-up/300550]` |
| **D20** | Day 28–32 | Chooses pharmacy and pays again for the 5 mg fill. | Same as D11–D17. | New order; new NCPDP ID; new price ($399 KwikPen/self-pay; $1,074.09 auto-injector; or insurance copay). | `[LIVE /api/external/medication_option_skus/710643/cash_price = 39900]`; `[LIVE /api/external/medication_option_skus/710646/cash_price = 107409]` |

**Timing note.** “4 weeks into tirzepatide” is 28 days of dosing, not 28 days from first click. If the first fill lands 2–5 days after the visit, D18–D20 are D+30 to D+35 from the click. The label’s week-4 step is the trigger, not a calendar reminder. `[PUBLIC Zepbound SPL §2.2]`

### 1.1 Label-based tirzepatide regimen (the clinical decision)

**Zepbound — weight reduction / OSA.** `[PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §§1–2, 4–5, 8.1]`

| Element | Label instruction |
|---|---|
| Indication (weight) | Adults with obesity (**BMI ≥30 kg/m²**), or overweight (**BMI ≥27 kg/m²**) with at least one weight-related comorbid condition; adjunct to a reduced-calorie diet and increased physical activity. |
| Indication (OSA) | Moderate-to-severe obstructive sleep apnea in adults with obesity. |
| Starting dose | **2.5 mg subcutaneously once weekly for 4 weeks.** The 2.5 mg dose is for treatment initiation and is **not** a maintenance dosage. |
| First escalation | After 4 weeks, increase to **5 mg subcutaneously once weekly.** |
| Further titration | Increase in **2.5 mg increments only after at least 4 weeks on the current dose**; consider treatment response and tolerability; if a maintenance dose is not tolerated, consider a lower maintenance dose. |
| Maintenance (weight) | **5 mg, 10 mg, or 15 mg subcutaneously once weekly.** |
| Maintenance (OSA) | **10 mg or 15 mg subcutaneously once weekly.** |
| Maximum | **15 mg subcutaneously once weekly for all indications.** |
| Administration | **Once weekly** at any time of day, with or without meals; abdomen, thigh, or upper arm; rotate injection sites. |
| Missed dose | Take within **4 days (96 hours)** of the missed dose; if more than 4 days have passed, skip and resume the regular day. The weekly day can change if at least **3 days (72 hours)** separate doses. |
| §4 contraindications | Personal or family history of **medullary thyroid carcinoma (MTC)**; **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)**; **known serious hypersensitivity** to tirzepatide or any excipient. |
| §5 precautions (not §4) | Severe GI adverse reactions; **not recommended in severe gastroparesis**; acute kidney injury from volume depletion; acute gallbladder disease; acute pancreatitis (discontinue if suspected); hypersensitivity reactions; hypoglycemia with insulin/secretagogue; diabetic retinopathy complications in T2D; pulmonary aspiration during general anesthesia/deep sedation; never share a KwikPen. |
| Pregnancy | May cause fetal harm; discontinue when pregnancy is recognized; counsel on non-oral contraception or a barrier method for 4 weeks after initiation and after each dose escalation. |

**Mounjaro — type 2 diabetes.** `[PUBLIC Mounjaro SPL §1, §2.1 (DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0)]`

- Indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients **10 years and older** with type 2 diabetes mellitus.
- **2.5 mg subcutaneously once weekly** starting dose; after 4 weeks increase to **5 mg once weekly**; if additional glycemic control is needed, **2.5 mg increments after at least 4 weeks** on the current dose.
- Maximum **15 mg once weekly in adults; 10 mg once weekly in pediatric patients 10 years and older.**
- **No BMI threshold** — the Zepbound BMI criteria do not apply to Mounjaro.

**What GM’s public guide adds (screening, not label).** BMI ≥30 or ≥27 with a weight-related condition; screen for MTC/MEN2, pancreatitis, gastroparesis, eating disorder, pregnancy; baseline HbA1c/CMP/TSH/lipids; monthly visits during titration, then roughly every 3 months. These are GM clinical-protocol choices; only MTC/MEN2 and serious hypersensitivity are label §4 contraindications. `[LIVE https://generalmedicine.co/resources/using-a-glp-1-for-weight-loss, 2026-10-19]`

---

## 2. Handoffs table

One row per GM ↔ outside-party exchange on this path. “Who pays” is the payer of the counterparty’s service, not the patient’s drug cost unless stated.

| Handoff | Counterparty (company + product) | Direction | What is exchanged (fields) | Mechanism | Trigger | Who pays / fee | Evidence |
|---|---|---|---|---|---|---|---|
| **H1** | **Emerald Medical Practice, P.C./P.A.** (AZ, CA, KS per current docs) | GM → PC | Clinician identity/NPI; state license; patient encounter; signed order; billing | Employment/1099 contract + Visitron assignment; PC is the furnishing/billing entity | Patient booked in a state served by an Emerald PC | Patient pays visit fee/copay to PC/GM; PC bills insurer | `[LIVE /terms-of-service; /telehealth-informed-consent; /assignment-of-benefits]`; `[LIVE https://generalmedicine.co/clinician-hiring]` |
| **H2** | **Ruby Medical Practice, P.C.** (NJ), **Centennial Medical Practice, P.C.** (ID) | GM → PC | Same as H1 | Same as H1 | Patient in NJ/ID (or as configured) | Same as H1 | `[LIVE /terms-of-service; /telehealth-informed-consent]`; `[PUBLIC NPPES 1346050150, 1174333975]` |
| **H3** | **OpenLoop Healthcare Partners, PC / Reliant.MD / MECNB** (under “Vital” consent) | GM → delegated network | Patient, encounter, consent, treatment | Professional-network contract; state-specific PCs; telehealth consent | If patient state/service is routed to delegated network (exact trigger not observed) | Network entity bills; GM coordinates | `[LIVE /vital-informed-consent, 2026-10-19]`; `[DOC adversarial-and-market-report.md §3.1]` |
| **H4** | **Athenahealth** | GM → Athena | Encounter note, diagnoses, orders, care plan, patient `athena_id` | REST API (`sync_encounter_to_athena`, `care_plan_athena_resync`, `encounter_summary_athena_resync`) | Clinician publishes/signs encounter | GM license | `[DATA internal_portals_recon.json → visitron]`; `[DOC architecture.md §8.2]` |
| **H5** | **DoseSpot** | GM ↔ DoseSpot | Patient meds, draft/final Rx, EPCS identity, formulary, eligibility, inbound refill requests | SSO + REST (`dose_spot_sso`, `prescription_eligibility_inquiries/*`, `escribe/*`) | Clinician prescribes or refills | GM license | `[DATA internal_portals_recon.json → visitron]`; `[DOC architecture.md §8.2]` |
| **H6** | **Nabla** | GM ↔ Nabla | Audio/transcript → note draft; status | Embedded scribe; only `get_nabla_status` recovered | Clinician starts scribe | GM license | `[DATA internal_portals_recon.json → visitron]`; `[DOC architecture.md §8.2]` |
| **H7** | **Arrive Health** | GM ↔ Arrive | Patient + drug + pharmacy → copay, deductible, formulary, PA signal; `arrive_rtpbi_inquiry_id` | OAuth launch + REST (`launch_benefit_inquiry`, `patient_context`, `pharmacy_pricing/insurance`) | Clinician price check / patient pharmacy selection | GM per-transaction fee (amount unknown) | `[DATA internal_portals_recon.json → visitron; catalog]`; `[CODE lib/store/api/pharmacyOrderApi.ts:99]` |
| **H8** | **Metriport + Particle Health** | GM ← HIE | Longitudinal records, meds, allergies, prior encounters | REST (`trigger_metriport_sync`), prewarm | Chart prep / General AI prewarm | GM license | `[DATA internal_portals_recon.json → visitron]`; `[DOC generalmedicine.md §7]` |
| **H9** | **Stripe** | GM ↔ Stripe | Card token, SetupIntent, payment method, charge, refund | Stripe.js/Elements; `payment_method_id`; `return_url` | Visit payment / pharmacy pre-pay | Patient pays; GM pays Stripe processing | `[CODE lib/api/endpoints.ts:321-328]`; `[LIVE /terms-of-service]` |
| **H10** | **LillyDirect Pharmacy, LLC** (NCPDP `1574056`) | GM → LillyDirect | Rx, patient name/DOB/contact, NCPDP ID, payment/insurance context | eRx to NCPDP ID; phone/fax fallback; LillyDirect’s dispensing pharmacy contacts patient | Patient selects LillyDirect | GM pay-ahead is not available at mail order; patient pays the LillyDirect dispensing pharmacy | `[LIVE /api/external/pharmacy_detail_pages/88334]`; `[LIVE LillyDirect FAQ]`; `[LIVE pay-ahead article]` |
| **H11** | **Amazon Pharmacy** (NCPDP `5919177`, A.E. Pharmacy, LLC) | GM → Amazon | Same as H10 | eRx to NCPDP ID | Patient selects Amazon | Patient pays Amazon | `[LIVE /api/external/pharmacy_detail_pages/36035]`; `[PUBLIC NPPES 1285084467]` |
| **H12** | **NovoCare** (NCPDP `5758074`, CoAssist Pharmacy, LLC) | GM → NovoCare | Same as H10, for Wegovy | eRx to NCPDP ID | Patient selects NovoCare | Patient pays NovoCare | `[LIVE /api/external/pharmacy_detail_pages/84293]`; `[PUBLIC NPPES 1710671854]` |
| **H13** | **CVS / Walgreens / Walmart / other retail** | GM → pharmacy | Rx, NCPDP ID, patient demographics, prepaid notice or GM card | eRx + NCPDP; GM card BIN/PCN; payment card texted for pre-pay | Patient selects retail | Cash: patient pays GM or pharmacy; insurance: PBM pays pharmacy, patient pays copay | `[CODE select_pharmacy; gm_card]`; `[LIVE /pharmacy/walgreens-pharmacy/73542]`; `[LIVE pay-ahead article]` |
| **H14** | **PBM / payer** | Pharmacy ↔ PBM | Claim, member ID, NDC, days supply, copay, PA | NCPDP Telecommunication Standard (inferred) | Fill/adjudication | PBM pays pharmacy; patient pays copay | `[INFERENCE]` from `insurance` billing type and PA copy; `[LIVE /assignment-of-benefits]` |
| **H15** | **Lilly / Novo savings programs** | Manufacturer → pharmacy/patient | Savings card BIN/PCN; eligibility; PTR claim | Pharmacy claim + manufacturer PTR (EVERSANA at `eversana-ptr.virtualrx.co`) | Eligible insured or self-pay fill | Manufacturer funds; patient pays reduced copay | `[LIVE https://zepbound.lilly.com/savings, 2026-10-19]`; `[LIVE LillyDirect FAQ]` |
| **H16** | **LillyDirect dispensing pharmacy** | Pharmacy → patient | Verification, checkout link, price, delivery/pickup options, tracking | SMS/email; checkout chat | Rx received | Patient pays pharmacy | `[LIVE LillyDirect FAQ]` |
| **H17** | **Retail/LillyDirect pharmacy** | Pharmacy → GM | Inbound refill request, Rx status, rejection/PA request | eRx inbound (`EscribingInboundRequest`), fax, phone; GM message center subject `pharmacy_order` | Refill/claim issue | No direct fee | `[DATA internal_portals_recon.json → visitron]`; `[CODE lib/store/api/messageCenterApi.ts:19]` |
| **H18** | **GM care/ops → payer** | GM → payer | PA form, chart evidence, letter of medical necessity, appeal | Unknown: payer portal/fax/phone; Arrive ePA possible but not evidenced | PA required/denied | GM staff time | `[CODE lib/hardcoded-data/CategoryPages/medications.ts:43]`; `[LIVE /assignment-of-benefits]`; `[INFERENCE]` |

**Mechanism note.** The only routing key visible in the client is the NCPDP provider ID. The actual eRx transport (NCPDP SCRIPT 10.x via DoseSpot/Surescripts) is server-side and not observed. Do not build an integration plan that assumes GM exposes the raw eRx payload; it does not. `[INFERENCE]`

---

## 3. Ops touchpoints

Where a human acts, with the queue/tool and the SLA signal actually observed.

**Who furnishes the visit.** The current legal docs assign Emerald telehealth to five PCs: **Emerald Medical Practice, P.C. (AZ), Emerald Medical Practice, P.A. (KS), Emerald Medical Practice, P.C. (CA), Ruby Medical Practice, P.C. (NJ), Centennial Medical Practice, P.C. (ID)**. NPPES records behind the three known PC names resolve to **UT/FL/NJ**; the Vital consent adds **OpenLoop Healthcare Partners, PC / Reliant.MD / MECNB** and state variants. The exact state→entity routing is server-side (`appointment_location_state`, `practiceId`) and unresolved. Treat it as a config matrix, not a hardcoded list. `[LIVE /terms-of-service; /telehealth-informed-consent; /vital-informed-consent]`; `[PUBLIC NPPES]`

| Role | Where they sit | Queue / tool | What they do on this path | SLA / signal | Evidence |
|---|---|---|---|---|---|
| **Clinician (MD/DO/NP/PA)** | Visitron | `ProviderAppointments`, `PatientAppointments`, `requestChatVisit`, `getChatHistory`, `getDraftEncounter`, `publishDraftEncounter` | Review chart, conduct video/chat, decide tirzepatide, order labs, draft/finalize Rx, sign care plan | Video promise “today”; chat next window 10:00 MT; shift-based | `[LIVE /api/external/sku_options/300543]`; `[DATA internal_portals_recon.json → visitron]`; `[LIVE /clinician-hiring]` |
| **Clinical reviewer (ACR)** | Visitron | `getAsyncClinicalReview`, `submitAsyncClinicalReview`, `getAsyncClinicalReviewFileUploadPreview`, `getClinicianReviews`, `applyReview`, `rejectReview`, `confirmNoChange` | Review async submissions, request photos/files, approve/deny, escalate to 300591 if red flag | Unknown; ACR is enabled per price option and GLP-1 eval has no ACR option | `[DATA internal_portals_recon.json → visitron]`; `[CODE types/enums/sku-constants.ts:7-8]`; `[DOC architecture.md §10.3]` |
| **Care coordination / ops** | Nile-Core + Message Center + Referrals | `conversations`, `conversation_subjects` (includes `pharmacy_order`), `response_expectation`; Referrals promises queue | PA follow-up, pharmacy issues, reschedule, refill exceptions, patient messages | `response_expectation` is dynamic per thread; support Mon–Fri 9–9 ET | `[CODE lib/api/endpoints.ts:60-65]`; `[CODE lib/store/api/messageCenterApi.ts:19]`; `[DOC architecture.md §10.7]`; `[LIVE /faq]` |
| **Pharmacist (LillyDirect dispensing pharmacy)** | Amazon/Fuze/Gifthealth/Prescryptive/Walmart | Pharmacy system + checkout link | Verify Rx, check insurance/PA, apply savings, collect payment, ship/pickup | 3–5 business days to contact; 1–4 days to ship after checkout | `[LIVE LillyDirect FAQ]` |
| **Retail pharmacist** | CVS/Walgreens/Walmart | Pharmacy system | Adjudicate claim, dispense, counsel, collect copay or GM card | Same day–2 days (inferred) | `[INFERENCE]`; `[LIVE /pharmacy/walgreens-pharmacy/73542]` |
| **Medical Director** | Emerald PCs | Governance/sign-off | Clinical oversight, protocol approval, GLP-1 guide review | Not queue-based | `[LIVE GLP-1 guide byline Dr. Pallabi Sanyal-Dey]`; `[DOC adversarial-and-market-report.md §3.1]` |
| **Credentialing / licensure** | GM + PCs | `getStateOptions`, `appointment_location_state`, `practiceId` | Maintain state→clinician→PC matrix; block unsupported states | Per-state; not observable | `[DATA internal_portals_recon.json → visitron]`; `[CODE lib/routes/skuBooking.ts:53-59]` |
| **Finance** | GM | Stripe dashboard; `invoice`, `gm_card` | Reconcile visit/pharmacy payments, refunds, cancellation fees, chargebacks | Refunds 5–10 business days | `[LIVE /cancellation-policy, 2026-10-19]` |
| **Patient support** | GM | SMS 98528; `help@generalmedicine.co`; Message Center | Triage visit/pharmacy/PA issues | Mon–Fri 9–9 ET | `[LIVE /faq; /using-zoom; /cancellation-policy]` |
| **Engineering on-call** | GM | Visitron/Nile-Core | Athena/DoseSpot/Arrive/Nabla outage; stuck encounters; eRx failures | Unknown | `[INFERENCE]` from integration chokepoint; `[DOC architecture.md §8.2]` |

**Shift mechanics.** Visitron has `getPendingShiftCheckouts`, `createShiftCheckout`, `getShiftCheckoutStatus`, `extendChatShift`, `reclaimFinishedChatVisit`, `cancelWithoutFee`, `markVisitNoShow`, `rescheduleSameProvider`, `rescheduleAnyProvider`. This is a shift-based clinical labor model, not a salaried panel. The hiring page confirms **1099 flexibility**, “pick your own hours”, “employed provider group” + “contractor clinicians”. `[DATA internal_portals_recon.json → visitron]`; `[LIVE /clinician-hiring]`

---

## 4. Money

### 4.1 Visit fees (the clinical gate)

| Item | Cash | Insurance | Notes | Evidence |
|---|---:|---:|---|---|
| GLP-1 medication evaluation `300543` — video | **$100.00** | **$25.00 est.** | Insured price is an estimate; actual copay after claim | `[LIVE /api/external/sku_options/300543, 2026-10-19]`; `[LIVE /s/glp-1-medication-evaluation/300543]` |
| GLP-1 medication evaluation `300543` — chat | **$30.00** | **none** | Cash-only; no insurance sub-option | `[LIVE /api/external/sku_options/300543]` |
| Weight Loss Follow-Up `300550` — video | **$100.00** | **$25.00 est.** | Same structure; used for week-4 titration | `[LIVE /api/external/sku_options/300550]`; `[LIVE /s/weight-loss-follow-up/300550]` |
| Weight Loss Follow-Up `300550` — chat | **$30.00** | **none** | Cash-only | `[LIVE /api/external/sku_options/300550]` |
| Typical visit copay | — | **$25.00** | `TYPICAL_VISIT_COPAY_CENTS = 2500`; used for logged-out display and fallback | `[CODE lib/productDetailPage/resolveMedicationOptionVisitCost.ts:4]` |
| Cancellation / no-show fee | **$25.00 default** | — | Client fallback `2500`; fee-eligible visit types are **video only** (`video_visit`, `video_visit_with_specialist_consultation`), not chat; triggers: `late_customer_cancel`, `no_show`, `no_show_predicted`, `no_confirmation`, `no_id_verification`, `missing_insurance`; Medicaid patients exempt per live policy | `[CODE utils/cancellationFeeUtils.ts:6-26, 43-53]`; `[LIVE /cancellation-policy, 2026-10-19]` |
| HSA/FSA | Eligible | Eligible | GM card purchases are HSA/FSA eligible | `[LIVE pay-ahead article, 2026-10-05]` |

**Practical read.** For an insured patient, **video ($25) is cheaper than chat ($30)**. Chat is a cash convenience, not a discount. The 4-week titration visit adds another $25–$100, so the clinical gate alone is $50–$200 over the first two months, before drug cost.

### 4.2 Drug prices by channel (live, 2026-10-19)

All values are 28-day supply. “GM cash” is the live `/api/external/medication_option_skus/:id/cash_price`; “retail” is the live `/api/external/pharmacy_comparisons` row at San Francisco coordinates. Prices move; re-probe before quoting.

| Drug / form | GM cash | Manufacturer-direct / card | Walgreens | CVS | Notes |
|---|---:|---:|---:|---:|---|
| **Zepbound KwikPen 2.5 mg** (`710641`) | **$299.00** | LillyDirect **$299.00**; Amazon **$299.00** | **$496.12** | **$508.09** | GM price = Lilly self-pay card price; retail is ~66–70% higher |
| **Zepbound KwikPen 5 mg** (`710643`) | **$399.00** | LillyDirect **$399.00** | **$496.12** | **$508.09** | Retail flat at the 7.5 mg-tier price |
| **Zepbound KwikPen 7.5 mg** (`710644`) | **$449.00** | LillyDirect **$449.00** | **$496.12** | **$508.09** | 45-day refill condition for $449 |
| **Zepbound KwikPen 10/12.5/15 mg** (`710647/710654/710651`) | **$449.00** | LillyDirect **$449.00** | **$692.92** | **$709.69** | 45-day refill condition |
| **Zepbound auto-injector 2.5–15 mg** (`710642/710646/710649/710652/710658/710661`) | **$1,074.09** | Single-dose pen card: **$25 covered / $499 not covered** | **$1,074.09** | **$1,100.16** | Default PDP form; single-dose pen, not KwikPen |
| **Zepbound single-dose vial 2.5–15 mg** (`701542/706142/704052/706624/708202/701128`) | **null** | LillyDirect self-pay (public Dec-2025 price cut: $299/$399/$449; not live-verified on GM) | **null** | **null** | GM shows “Priced after visit”; no LillyDirect row in comparison |
| **Mounjaro auto-injector 2.5–15 mg** (`710655/710657/710662/710663/710664/710667`) | **$552.28** | No LillyDirect listing | **$552.28** | **$565.63** | T2D brand; retail only |
| **Foundayo (orforglipron) oral** (`706450`) | **$149.00** | LillyDirect **$149.00**; Amazon **$149.00** | **$643.72** | **$659.29** | Lilly oral GLP-1 |
| **Wegovy (injectable)** (`709551`) | **$149.00** | NovoCare **$149.00** | **$1,332.53** | **$1,364.91** | Novo direct-pay; PDP short description says weekly injection — verify form before quoting |
| **Ozempic (semaglutide, T2D)** (`711204`) | **$199.00** | NovoCare **$199.00** | **null** | **null** | Retail unpriced in this zip |

**The key price fact.** GM’s “from $299” is **consistent with a manufacturer self-pay pass-through**, not a GM-negotiated retail discount. At retail, the GM card price for the same 2.5 mg KwikPen is **$496.12** (Walgreens) / **$508.09** (CVS), which is higher than the 5 mg self-pay price ($399) and close to the 7.5 mg regular price ($499). The cheapest path is to route the Rx to **LillyDirect** (or Amazon/NovoCare), not to use the GM card at a retail counter. `[LIVE cash_price and pharmacy_comparisons, 2026-10-19]`; `[PUBLIC Zepbound savings terms: regular price $299/$399/$499/$699]`

### 4.3 The three cash/insurance rails (and a fourth)

| Rail | Billing type | What the patient pays | Where | Code/evidence | Operational consequence |
|---|---|---|---|---|---|
| **A. Cash pre-pay / GM card** | client `gm_card`; server `cash` | GM cash price at checkout | Stripe → GM; pharmacy told “prepaid”; virtual card texted | `[CODE lib/utilities.ts:949-955]`; `[CODE pharmacyOrderApi.ts:61-72]`; `[LIVE pay-ahead article]` | Pay-ahead works at **eligible retail pharmacies only**; not mail order. GM must reconcile every prepaid claim. |
| **B. Insurance** | `insurance` | Copay at counter (no app charge) | PBM adjudication; pharmacy collects | `[CODE pharmacyOrderApi.ts:73-80]`; `[DOC architecture.md §9.1 step 4]` | PA may be required; GM’s estimate is not a guarantee; savings card may reduce at counter. |
| **C. Pharmacy delegation** | client `pharmacy_delegated`; server `pharmacy_delegation` | Discounted price at pharmacy | Patient pays pharmacy; GM card BIN/PCN/group/member | `[CODE lib/utilities.ts:952-953]`; `[CODE pharmacyOrderApi.ts:81-88, 105-110]`; `[DOC openapi.yaml:1390-1420]` | GM does not take custody of drug or payment (per dossier); pharmacy claims through GM’s switch. |
| **D. Mail order (LillyDirect/Amazon/NovoCare)** | `pharmacy_delegation` (inferred) | Manufacturer self-pay price, paid to the pharmacy | Pharmacy checkout link | `[LIVE LillyDirect FAQ]`; `[INFERENCE]` mapping to pharmacy delegation | No GM pay-ahead; patient pays a third party; GM’s order record does not show payment. |

**The “General Medicine card” is two different artifacts.** The public article shows a card and says the pharmacy is told the Rx is prepaid; the API’s `gm_card` is a **BIN/PCN/group/member_id** pharmacy discount/claim-routing card. A prepaid payment card and a discount card are not the same instrument. The article uses one name for both. Build two distinct objects in the tech plan: (1) virtual payment card/Stripe charge, (2) discount/claim card. `[LIVE pay-ahead article]`; `[DOC openapi.yaml:1390-1420]`; `[INFERENCE]`

### 4.4 Manufacturer savings cards

**Zepbound KwikPen Self-Pay Savings Card** (the card that produces GM’s $299/$399/$449):
- 2.5 mg: as low as **$299**, max monthly savings **$215**.
- 5 mg: as low as **$399**, max monthly savings **$115**.
- 7.5/10/12.5/15 mg: as low as **$449**; first purchase qualifies, then **refill within 45 days** of the previous delivery.
- Regular price outside the offer: **$299 / $399 / $499 / $699 / $699 / $699** for 2.5/5/7.5/10/12.5/15 mg.
- **Cash only**, outside any health insurance; patient agrees not to seek reimbursement from any payer, including private insurance or government programs; “THIS CARD IS NOT INSURANCE.”
- Expires **12/31/2026**.
- Post-transaction reimbursement runs through **EVERSANA** (`eversana-ptr.virtualrx.co`).
`[PUBLIC https://zepbound.lilly.com/savings, 2026-10-19]`

**On-label requirement.** Both savings programs require a prescription for an “approved use consistent with FDA-approved product labeling.” An off-label BMI <27 prescription is not eligible for the Lilly self-pay/card price; the patient is in a retail-cash or insurance-denial path. `[PUBLIC https://zepbound.lilly.com/savings, 2026-10-19]`; `[LIVE GLP-1 guide]`

**Zepbound Single-Dose Pen (auto-injector) Savings Card:**
- Covered commercial: as low as **$25** per 1/2/3-month fill (max $100/$200/$300; $1,300/calendar year; 13 fills).
- Not-covered commercial: as low as **$499** per month.
- Excludes Medicare/Medicaid/TRICARE/VA/etc.
`[PUBLIC https://zepbound.lilly.com/savings, 2026-10-19]`

**Medicare GLP-1 Bridge:** eligible Medicare Part D patients with a Zepbound weight-management prescription may pay **no more than $50/month**; eligibility based on clinical criteria; not a guarantee of coverage. `[PUBLIC https://zepbound.lilly.com/savings, 2026-10-19]`

**What GM’s software does with these:** nothing observed. There is no savings-card field, BIN/PCN for a manufacturer card, or PTR object in the consumer API or Visitron. LillyDirect’s dispensing pharmacies apply eligible savings automatically; a retail pharmacy can apply a manufacturer card at the counter if the patient enrolled. GM’s insurance estimate may not reflect the card. `[INFERENCE]` from absence of fields + `[LIVE LillyDirect FAQ]` (“the dispensing pharmacy filling your prescription will apply the savings card automatically”)

### 4.5 Shipping, cold chain, and fees

- **LillyDirect home delivery is free.** Most prescriptions process/ship **1–4 days after checkout**; verification/checkout link takes **3–5 business days** after the Rx arrives. `[LIVE LillyDirect FAQ]`
- **Cold chain:** refrigerated medicines ship in cold-chain packaging; may not ship near weekends/holidays. Most shipments do not require a signature. `[LIVE LillyDirect FAQ]`
- **Label storage:** Zepbound and Mounjaro single-dose pens/vials **2–8°C (36–46°F)**; up to **21 days** at ≤30°C (86°F), one-way (do not return to refrigerator). `[PUBLIC Zepbound SPL §16.2]`; `[PUBLIC Mounjaro SPL §16.2]`
- **Retail pickup:** no shipping; patient picks up; pharmacy handles temperature during storage.
- **GM fees:** no shipping fee observed; no GM tracking/carrier field in `PharmacyOrder`. `[DOC openapi.yaml:243-273]`
- **Cancellation/refund:** fee charged to card on file; visit fees refunded automatically if fee applies; refunds 5–10 business days; no refunds for services provided or cancellation fees; Medicaid exempt. `[LIVE /cancellation-policy]`
- **ACR clinical review fee (not GLP-1):** in-person SKUs can bundle `coordination_fee` + `clinical_review_fee` into `checkout_fee`; live `300603` = $30 + $15 = **$45**, with `allows_acr: true`. `[LIVE /api/external/sku_options/300603]`; `[CODE OfficeVisitOption.tsx:52-57]`

### 4.6 What GM earns on the pharmacy leg

**Unknown.** The $299/$399/$449 Zepbound prices equal Lilly’s self-pay prices, which is consistent with a pass-through rather than a GM margin. The retail GM-card price is higher, consistent with a discount-card/claim-switch economics, but no fee, spread, or remittance field is exposed in the recovered source. Do not model pharmacy gross margin without a contract. `[INFERENCE]` from price equality + absence of fields.

---

## 5. Failure modes & branches

### 5.1 Clinical branches

| Branch / failure | What happens | Evidence |
|---|---|---|
| **Zepbound BMI <27** | Not on-label for Zepbound weight management; clinician may discuss off-label, typically not covered by insurance, and **not eligible for the Lilly self-pay/card price** (requires an approved-use prescription). Mounjaro (T2D) has no BMI threshold. | `[LIVE GLP-1 guide]` (BMI table); `[PUBLIC Zepbound SPL §1]`; `[PUBLIC savings terms]` |
| **Zepbound BMI 27–29.9 without comorbidity** | Not on-label; off-label/insurance denial likely; cash path may be retail, not the Lilly self-pay card. | `[PUBLIC Zepbound SPL §1]`; `[LIVE GLP-1 guide]`; `[PUBLIC savings terms]` |
| **Label §4 contraindication: MTC/MEN2** | Do not prescribe tirzepatide: personal or family history of medullary thyroid carcinoma, or MEN 2. | `[PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §4]` |
| **Label §4 contraindication: serious hypersensitivity** | Do not prescribe: known serious hypersensitivity to tirzepatide or any excipient (anaphylaxis/angioedema reported). | `[PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §4, §5.6]` |
| **Label precautions (not §4)** | Severe gastroparesis (not recommended), acute pancreatitis (discontinue if suspected), acute gallbladder disease, AKI from volume depletion, hypoglycemia with insulin/secretagogue, diabetic retinopathy in T2D, pulmonary aspiration under anesthesia, pregnancy (may cause fetal harm; discontinue when recognized). Clinician judgment/monitoring, not an automatic contraindication. | `[PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §5, §8.1]` |
| **GM protocol screening exclusion (not label §4)** | Active eating disorder / significant body-image concerns; GM’s clinical-protocol exclusion. | `[LIVE GLP-1 guide]` |
| **Abnormal baseline labs** | Hold/adjust; repeat labs; may delay first fill. | `[LIVE GLP-1 guide]` (baseline and 3–6 month repeat); `[INFERENCE]` |
| **Patient on another GLP-1** | Clinician may switch; label says coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is **not recommended**. | `[PUBLIC https://pi.lilly.com/us/zepbound-uspi.pdf §1 Limitations of Use]`; `[LIVE GLP-1 guide]` |
| **Under 18** | Not eligible for GM; adult-only service. | `[LIVE /faq]` |
| **State not supported** | Booking/state confirmation should block; exact copy not recovered. | `[CODE lib/routes/skuBooking.ts:53-59]`; `[INFERENCE]` |

### 5.2 Insurance / PA branches

| Branch / failure | What happens | Evidence |
|---|---|---|
| **PA required** | RTPB flags it; GM/LillyDirect/pharmacy coordinates; **several business days**; patient may wait. | `[LIVE GLP-1 guide]`; `[LIVE LillyDirect FAQ]`; `[LIVE Zepbound PDP FAQ]` (“prior authorization is commonly required”) |
| **PA denied** | Cash/self-pay or alternative; GM testimonial claims follow-through after denial, but no PA appeal object/queue exists in recovered software. | `[CODE testimonials.ts:50,61]`; `[DATA visitron ops]`; `[INFERENCE]` manual |
| **Plan does not cover weight management** | Cash path; **Medicare Part D usually does not cover** Zepbound for weight management alone. | `[LIVE Zepbound PDP FAQ]`; `[LIVE GLP-1 guide]` |
| **Medicare Part D** | Possible GLP-1 Bridge ≤$50/mo if eligible; otherwise cash/self-pay. | `[PUBLIC zepbound.lilly.com/savings]` |
| **Medicaid** | Cancellation fee exempt; GLP-1 coverage varies; manufacturer savings cards exclude government payers. | `[LIVE /cancellation-policy]`; `[PUBLIC savings terms]` |
| **Insurance estimate wrong** | Patient sees “est.” price; actual copay set at adjudication; GM’s tooltip says price is only known after prescription. | `[CODE MedicationPriceCard.tsx:14-15]`; `[LIVE PDP]` (“Available after visit”) |
| **Patient selects LillyDirect while insured** | LillyDirect self-pay is cash-only; patient agrees not to seek insurance reimbursement; no PA needed. For insurance, the patient should use a retail pharmacy or a LillyDirect insurance-eligible medicine. `[INFERENCE]` from the self-pay terms. | `[LIVE LillyDirect FAQ]`; `[PUBLIC savings terms]` |
| **Patient selects Walmart pickup via LillyDirect** | $299 self-pay; patient agrees not to seek reimbursement; this is a different channel from Walmart retail (NCPDP 0511053, $496.12). | `[LIVE LillyDirect FAQ]`; `[LIVE pharmacy_comparisons 710641]` |

**PA read (direct answer).** The only PA-adjacent software on this path is the RTPB layer: Arrive Health (`launch_benefit_inquiry`) and DoseSpot (`prescription_eligibility_inquiries/*`) return copay/formulary/PA requirements; neither exposes a PA submission or appeal object in the recovered ops. There is no CoverMyMeds/Surescripts integration in source or DNS. Who files is therefore **not established**: GM marketing says it handles PAs, the Assignment of Benefits says the patient/referring physician is responsible, and LillyDirect says it coordinates PAs with the provider and insurer. Timing: “several business days” (GM GLP-1 guide); LillyDirect allows 3–5 business days for Rx verification before its checkout link. Model PA as a manual ops queue with a case record you build, not as a recovered GM workflow. `[CODE lib/hardcoded-data/CategoryPages/medications.ts:43]`; `[LIVE /assignment-of-benefits]`; `[LIVE GLP-1 guide]`; `[LIVE LillyDirect FAQ]`; `[DATA internal_portals_recon.json → visitron]`

### 5.3 Fulfillment / pharmacy branches

| Branch / failure | What happens | Evidence |
|---|---|---|
| **Patient selects auto-injector (default PDP)** | Pays **$1,074.09** (Walgreens/Walmart) or **$1,100.16** (CVS), not $299. The single-dose pen is not the KwikPen self-pay tier. | `[LIVE PDP selected_sku_id=710642; cash_price=107409]`; `[PUBLIC savings terms]` |
| **Patient selects vial** | No GM cash price; “Priced after visit”; not routed to LillyDirect; retail comparison all null. | `[LIVE 701542 cash_price=null]`; `[LIVE comparison 701542]` |
| **Patient selects Mounjaro** | Retail only; no LillyDirect; $552.28 cash at Walgreens, $565.63 at CVS; insurance/PA for T2D. | `[LIVE 710655]`; `[LIVE LillyDirect medications list]` |
| **Out of stock at retail** | No inventory signal in GM; patient/pharmacy must discover it; remedy is cancel/switch pharmacy or wait. | `[LIVE comparison fields: no in_stock]`; `[CODE cancel + can_switch_pharmacy]` |
| **Out of stock at LillyDirect** | LillyDirect says prescriptions can still be filled with a slight delay during limited availability; no GM substitution logic. | `[LIVE LillyDirect FAQ]` |
| **Pharmacy never receives eRx** | Patient sees no fill; must text 98528 / message; GM has no eRx acknowledgment field in the consumer schema; known 1-star complaint pattern. | `[LIVE /using-zoom; /faq]`; `[DOC adversarial-and-market-report.md §5.5]`; `[INFERENCE]` |
| **Claim rejected at counter** | Patient pays cash or resolves PA; GM’s app has no claim-rejection state. | `[INFERENCE]`; `[DOC PharmacyOrder state model]` |
| **Patient wants to switch pharmacy after order placed** | `POST /pharmacy_orders/:id/cancel { pharmacyChange: true }`; response returns `can_cancel_pharmacy_order`, `can_switch_pharmacy`, `can_choose_new_pharmacy`; may require new order. | `[CODE pharmacyOrderApi.ts:12-24, 46-59]`; `[DOC architecture.md §9.1 step 6]` |
| **Patient wants to transfer an existing Rx** | No transfer API. “Request a prescription” starts a clinical review/booking flow; LillyDirect says ask the provider to send a new Rx; retail-to-retail transfer is pharmacy-mediated. | `[CODE RequestPrescriptionCard.tsx:47-66]`; `[LIVE LillyDirect FAQ]`; `[LIVE /pharmacy/walgreens-pharmacy/73542]` (“Start with a clinical review”) |
| **Dose change at week 4** | Pharmacy will **not** auto-adjust; each new dose needs a new Rx. If the patient misses the check-in, no refill. | `[LIVE LillyDirect FAQ]` (“Each new dose typically requires an updated prescription”); `[PUBLIC Zepbound SPL §2.2]` |
| **Refill with no refills left** | Clinician renewal required; may require questionnaire/labs/visit. | `[CODE lib/hardcoded-data/CategoryPages/medications.ts:160-161]`; `[LIVE /resources/medication-faqs]` |
| **Cold-chain failure** | Replace via pharmacy; no GM tracking/temperature telemetry. | `[LIVE LillyDirect FAQ]`; `[PUBLIC label]`; `[INFERENCE]` |

### 5.4 Software / contract risks exposed by this file

| Risk | Why it matters | Evidence |
|---|---|---|
| **Billing-type enum mismatch** (`gm_card`/`pharmacy_delegated` vs `cash`/`pharmacy_delegation`) | A branch may never fire or may send an invalid enum; pharmacy payment logic is the highest-risk place for a silent bug. | `[CODE lib/utilities.ts:949-955]`; `[DOC openapi.yaml:257-262, 1241-1246]` |
| **`hasClinicalReview` source unknown** | `billingTypeRequiresPayment` depends on it for insurance/pharmacy-delegation; no field in `PharmacyOrder` schema. | `[CODE lib/utilities.ts:949-955]`; `[DOC openapi.yaml:243-273]` |
| **`default_quantity` unit inconsistency** | Could generate a 14-day Mounjaro supply or a 56-day Zepbound supply; pharmacy may correct silently, masking the defect. | `[LIVE PDP 710642, 710655]` |
| **`201448` first-fill=false** | New patient can be routed to a SKU that does not allow first fill from the Lilly page; may dead-end or misclassify intake. | `[DATA 201448.modalities]`; `[LIVE Lilly page]` |
| **No `in_stock`** | Cannot automate out-of-stock routing; ops must call/switch. | `[LIVE comparison fields]` |
| **No tracking/carrier in `PharmacyOrder`** | Patient support cannot answer “where is my package?” from GM data; must use pharmacy. | `[DOC openapi.yaml:243-273]` |
| **Chat price fallback $35** | Code fallback is `$35`; live price is `$30`. If the price payload misses, the user sees the wrong price. | `[CODE components/VisitOptions/ChatVisitOption.tsx:32]`; `[LIVE 3000]` |
| **No PA object** | PA work is invisible to analytics and SLAs; cannot measure denial/appeal rates. | `[DATA visitron; consumer endpoints]` |
| **No manufacturer savings-card field** | Cannot show the real out-of-pocket (e.g., $25 with Zepbound card) or reconcile PTR. | `[INFERENCE]` from absence; `[PUBLIC savings terms]` |
| **Two telehealth consents** (Emerald vs Vital/OpenLoop) | Which entity furnishes a given GLP-1 visit is not determinable; consent/records/billing may be misattributed. | `[LIVE /telehealth-informed-consent; /vital-informed-consent]` |
| **PC state list vs NPPES mismatch** | Compliance/credentialing risk; state→PC matrix cannot be trusted from either source alone. | `[LIVE ToS/consent]`; `[PUBLIC NPPES]` |

---

## 6. Open questions

1. **State→PC mapping.** Which Emerald PC furnishes a GLP-1 visit in each state, and is the `practiceId` in the booking flow a PC ID, a tenant ID, or a clinician-group ID? The client only carries the value; the assignment is server-side.
2. **OpenLoop/Vital role.** Is the Vital/OpenLoop/Reliant/MECNB consent used for GLP-1 visits in states without an Emerald PC, or is it legacy/for another service line? Two telehealth consents coexist.
3. **Async GLP-1 review.** Does any GLP-1 case use `AsyncClinicalReview` before/after the video/chat visit? The SKU has no `allows_acr`, but the FAQ advertises an “asynchronous consult within 24–48 hours” after General AI. Is that a different product or the same chat modality?
4. **PA vendor and queue.** Who actually submits the PA (GM ops, clinician, retail pharmacy, LillyDirect dispensing pharmacy)? Is Arrive Health’s ePA module used, or only RTPB? Is there a denial/appeal queue? No PA object exists in the recovered software.
5. **PA timing.** GM says “several business days”; LillyDirect says 3–5 business days for Rx verification; what is the measured p50/p90 for GLP-1 PA?
6. **Pharmacy economics.** Does GM earn a spread, a discount-card fee, or a manufacturer/partner fee on any pharmacy leg? The $299 price equality suggests pass-through, but there is no contract evidence.
7. **Manufacturer savings cards in GM checkout.** Can a patient attach a Zepbound/Novo savings card in GM’s insurance path, or only at the pharmacy counter? No field exists.
8. **Week-4 requirement.** Is the 4-week titration step a paid follow-up visit (`300550`), a questionnaire-only check-in, or either? The label requires a dose decision; the CareJourney can gate on Questionnaire, Lab, or Visit.
9. **Clinical SLAs.** What are the promised response times for chat visits, video starts, ACR decisions, and PA updates? `response_expectation` is dynamic; no static SLA is published.
10. **Out-of-stock handling.** Is there a pharmacy status feed (NCPDP/NCPDP SCRIPT confirmation, backorder, partial fill) that GM consumes server-side but does not expose? The client has no `in_stock` or rejection state.
11. **Tracking.** Does GM ingest carrier/tracking from LillyDirect/Amazon/retail? `PharmacyOrder` has no tracking fields.
12. **Quantity unit.** Is `default_quantity` mL or pens? Mounjaro’s `1.0` for 28 days is inconsistent with a 4-pen supply.
13. **Default form intent.** Why is the Zepbound PDP default the auto-injector ($1,074.09) rather than the KwikPen ($299)? Is this a clinical default (single-dose pen preferred) or a catalog artifact?
14. **`201448` CTA.** Is the Lilly page’s Zepbound CTA to a `first_fill:false` SKU intentional (existing patients) or a funnel bug for new starts?
15. **Transfer flow.** Can a patient move an existing Rx from another pharmacy without a new GM visit? The only observed path is a new clinical review/Rx.
16. **LillyDirect insurance eligibility.** LillyDirect accepts insurance for “select medicines”; which GLP-1 SKUs are insurance-eligible vs self-pay-only? GM’s comparison does not label this.
17. **Who collects the $299.** Does GM collect the KwikPen self-pay price and remit to LillyDirect, or does the patient pay LillyDirect directly? The public article says pay-ahead is retail-only; the order schema does not distinguish.
18. **`gm_card` funding.** Who sponsors the BIN/PCN, what is the discount formula, and is the card the same instrument as the “prepaid” card in the article?
19. **Clinical review fee applicability.** Does a GLP-1 pharmacy order ever carry a `clinical_review_fee` (e.g., questionnaire-only renewal), or is the visit fee the only clinical charge?
20. **ACR for GLP-1 in any state.** Could a state or protocol route a GLP-1 case through ACR despite the current SKU configuration? The SKU data says no; the Visitron capability exists.
21. **`pharmacy_delegated` enum.** Is the client literal a typo, a legacy alias, or the actual server value? This must be resolved before building payment reconciliation.
22. **Pharmacy directory indexing.** The directory pages are `noindex,nofollow`; are they intended as SEO surfaces or only in-app navigation? (Acquisition file.)

---

## 7. Handoff to other evidence files

- **Handoff to Acquisition:** The Lilly partner page’s Zepbound CTA goes to `201448` (`allows_first_fill:false`, `allows_refill:true`), while the new-start path is `300543`. The page advertises “from $299” but the default PDP is the auto-injector at $1,074.09. Fix or explain before scaling paid traffic. Also: pharmacy directory pages are `noindex,nofollow`.
- **Handoff to Intake:** State confirmation and `practiceId` are the only visible routing signals; the questionnaire UUIDs for `300543` are `11340c6b-1296-4c46-ad5b-1e9c48474084` (screening) and `3cdcfa37-64a0-4257-964b-9a41209b1f29` (history), and for `201448` `e286b849-9076-44f3-bd2b-a590d877495a` / `140be43a-30ca-44e0-95b3-dfb3f5cbc839`. Use these to join intake answers to the clinical decision. `[DATA extracted_care_plans_and_journeys.json]`
- **Handoff to FirstMonth:** The week-4 state is a CareJourney check-in (`/prescriptions/:id/check-in`) plus a possible `300550` visit and a new Rx for 5 mg. The 5 mg KwikPen cash price is $399; the auto-injector is $1,074.09; insurance copay depends on PA. Build the titration reminder around the label’s 4-week step, not a generic 30-day refill.
- **Handoff to CheckoutLabs:** The three billing rails (`gm_card`/`cash`, `insurance`, `pharmacy_delegated`/`pharmacy_delegation`), the $25 default cancellation fee (video only), and the pay-ahead vs pay-at-pharmacy split all need one owner. The enum mismatch and `hasClinicalReview` source are blockers for a clean payment model.
- **Handoff to Backoffice:** Visitron is the integration chokepoint: Athena, DoseSpot, Nabla, Arrive, Metriport. The shift/checkout model and provider notifications are the clinician queue. PA work has no object; it needs a queue/tool and an SLA before the operating plan can staff it.

---

### Source appendix (live probes and public sources)

All live GETs were unauthenticated, read-only, and made 2026-10-19 PT / 2026-10-20 UTC. No account, form, checkout, or personal data was submitted.

- `https://generalmedicine.co/s/glp-1-medication-evaluation/300543`
- `https://generalmedicine.co/s/weight-loss-follow-up/300550`
- `https://generalmedicine.co/s/zepbound-tirzepatide/201448` → `/dp/zepbound/710642`
- `https://generalmedicine.co/s/mounjaro-tirzepatide/201446` → `/dp/mounjaro/710655`
- `https://generalmedicine.co/dp/zepbound/710642`
- `https://generalmedicine.co/p/lilly/weight-loss`
- `https://generalmedicine.co/pharmacy/lillydirect/88334`
- `https://generalmedicine.co/pharmacy/walgreens-pharmacy/73542`
- `https://generalmedicine.co/api/external/sku_options/{300543,300550,201448,300603}`
- `https://generalmedicine.co/api/external/product_detail_pages/{710642,710655}`
- `https://generalmedicine.co/api/external/medication_option_skus/{710641,710642,710643,710644,710646,710647,710649,710651,710652,710654,710658,710661,701542,706142,704052,706624,708202,701128,710655,710657,710662,710663,710664,710667,706450,709551,711204}/cash_price`
- `https://generalmedicine.co/api/external/pharmacy_comparisons?medication_option_sku_id={710641,710642,701542,710655,706450,709551,711204}&latitude=37.7749&longitude=-122.4194`
- `https://generalmedicine.co/api/external/pharmacy_detail_pages/{88334,36035,84293}`
- `https://generalmedicine.co/api/external/pharmacy_detail_pages/88334/medications?page=1&per_page=50`
- `https://generalmedicine.co/api/external/search/index?query={compounded,tirzepatide,semaglutide,zepbound,mounjaro}`
- `https://generalmedicine.co/terms-of-service`
- `https://generalmedicine.co/telehealth-informed-consent`
- `https://generalmedicine.co/vital-informed-consent`
- `https://generalmedicine.co/assignment-of-benefits`
- `https://generalmedicine.co/cancellation-policy`
- `https://generalmedicine.co/faq`
- `https://generalmedicine.co/resources/using-a-glp-1-for-weight-loss`
- `https://generalmedicine.co/resources/medication-faqs`
- `https://generalmedicine.co/resources/compare-medication-prices-before-you-order-and-pay-ahead-for-easy-pickup`
- `https://generalmedicine.co/clinician-hiring`
- `https://generalmedicine.co/using-zoom`
- `https://www.lilly.com/lillydirect/faq`
- `https://zepbound.lilly.com/savings`
- `https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html` (public report of the Dec-2025 vial price cut; Lilly investor PDF returned 403)
- `https://npiregistry.cms.hhs.gov/api/?number={1912889320,1285084467,1710671854,1447011267,1750195483,1174333975,1346050150}&version=2.1`
- `https://api.fda.gov/drug/label.json?search=openfda.brand_name:"ZEPBOUND"` and `"MOUNJARO"`
- `https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/{d2d7da5d-ad07-4228-955f-cf7e355c8cc0}.xml`
- `https://www.pharmacytimes.com/view/manufacturer-bypasses-traditional-channels-to-sell-directly-to-patients-and-it-makes-perfect-sense`
- `https://corporate.walmart.com/news/2025/10/29/lillydirect-and-walmart-pharmacy-launch-first-retail-pick-up-option-with-direct-to-consumer-pricing-for-zepbound`
